New Class of Treatment for Overactive Bladder Approved in Europe (y 2)

        
        1) Data on file
        2) Benner J.S., Nichol M.B., Rovner E.S., et al. Patient-reported reasons for
          discontinuing overactive bladder medication. BJU Int 2010; 105(9): 1276-82
        3) Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed
          antimuscarinic therapy for overactive bladder: a UK experience. BJUI 2011.
          Doi:10.1111/j.1464-410X.2012.11023.x
        4) Abrams P. et al. Reviewing the ICS 2002 Terminology Report: The Ongoing
          Debate. Neurourol Urodyn 2006; 25: 293-294
        5) Irwin D.E., et al.Worldwide prevalence estimates of lower urinary tract
          symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.
          [http://www.ncbi.nlm.nih.gov/pubmed/21231... ]BJU Int 2011; 108(7):1132-8
        6) Milsom I et al. How widespread are the symptoms of an overactive bladder and
          how are they managed? A population-based prevalence study. BJU Int 2001;87(9)760-6
        7) Brown J.S. et al. Comorbidities associated with overactive bladder. Am J
          Manag Care 2000; 6(11 Suppl): S574-579
        8) Stewart WF et al. Prevalence and burden of overactive bladder in the United
          States. World J Urol 2003; 20: 327-336
        9) Khullar V et al. Efficacy of mirabegron in patients with and without prior
          anti-muscarinic therapy for overactive bladder (OAB): Post-hoc analysis of a
          prospective, randomised European-Australian phase III trial. EAU 2012 Poster
          AM12-2389 10) Tyagi P et al. Mirabegron: safety review Expert Opin. Drug Safety
          2011;10.2: 287-294
          11) Khullar V., Amarenco G., Angulo J.C., et al. Efficacy and safety of
          mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder:
          results from a randomized European-Australian phase 3 trial. Eur Urol 2012;
          http://dx.doi.org/10.1016/j.eururo.2012....
          12) Nitti V., Auerbach A., Martin N., et al. Results of a randomized phase III
          trial of mirabegron in patients with overactive bladder. J Urol 2012;
          10.1016/j.juro.2012.10.017
          13) Van Kerrebroeck P, Barkin J, Castro-Diaz D et al. Randomised, double-blind,
          placebo-controlled Phase III study to assess the efficacy and safety of mirabegron 25
          mg and 50 mg once daily in overactive bladder (OAB). Presented at ICS 2012.
          14) Chapple CR., Kaplan SK., Mitcheson D., et al. Randomized double-blind,
          active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron,
          a beta3-adrenoceptor agonist, in overactive bladder. Eur Urol 2012;
          http://dx.doi.org/10.1016/j.eururo.2012....
          15) Nitti V et al. Mirabegron improves patient-reported outcomes in patients
          with overactive bladder syndrome - results from a North-American study. Presented at
          AUA 2011

CONTACT: For further information please contact: Julia Holt,Red Door Communications, jholt@rdcomms.com, Tel: +44(0)20-8392-8052,Mobile: +44(0)7788-441422; Mindy Dooa,Astellas Pharma Europe Ltd., Mindy.Dooa@astellas.comMobile: +44(0)7826-912-339